Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309663 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL12136815 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL14543695 | 0.94 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL19240727 | 0.94 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL22624346 | 0.92 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL19426075 | 0.87 | CYP1A2 (0.55) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL478542 | 0.86 | — | — | |
| SCHEMBL14818634 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAPOLBMEN1MAPT | |
| SCHEMBL12142184 | 0.86 | — | — | |
| SCHEMBL19102936 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAPOLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | claimed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | claimed |
| US-7939548-B2 | Aminopyridines, e.g.,N-{[6-(aminomethyl)(2-pyridyl)]methyl}(2-{[2-(3-fluorophenyl)ethyl]amino}-5-(3-pyridyl)(3-pyridyl))carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-05-10 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | claimed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | claimed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-05 | — | — | US | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-6099907-A | MIXING A SOLVENT FOR POLYANILINE WITH A SECONDARY AMINE; GELATION INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-08 | — | — | US | claimed |
| EP-1008148-A1 | STABLE, CONCENTRATED SOLUTIONS OF HIGH MOLECULAR WEIGHT POLYANILINE AND ARTICLES THEREFROM | The Regents of The University of California (US) | 2000-06-14 | — | — | EP | claimed |
| US-5981695-A | MIXING SOLVENT FOR POLYANILINE WITH SECONDARY AMINE SUCH THAT THE MOLAR RATIO OF SECONDARY AMINE TO POLYANILINE TETRAMER REPEAT UNIT IS BETWEEN 0.1 AND 5.0, FORMING THEREBY A SOLUTION; DISSOLVING THE POLYANILINE IN THE SOLUTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-09 | — | — | US | claimed |
| WO-1997045842-A1 | STABLE, CONCENTRATED SOLUTIONS OF HIGH MOLECULAR WEIGHT POLYANILINE AND ARTICLES THEREFROM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-04 | — | — | WO | claimed |
| US-5665504-A | Simulated photographic-quality prints using a plasticizer to reduce curl | XEROX CORPORATION (US) | 1997-09-09 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ALDH1A1 1756/4885LMNA 242/4885POLB 2598/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | ALDH1A1 2830/4885LMNA 605/4885POLB 4216/4885 |
| US-20080132545-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ALDH1A1 1756/4885LMNA 242/4885POLB 2598/4885 |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ALDH1A1 1756/4885LMNA 242/4885POLB 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.